title: [Medical progress exemplified by improvements in the safety coronary angioplasty].
abstract: The significant decrease in complications associated with coronary angioplasty is a model of medical progress. Breakthroughs are achieved through individual initiatives, whereas incremental progress results from occasional, anonymous improvements. The two types of improvement are complementary, as pointed out by Claude Bernard as early as 1864.
authors.affiliation: Institut de Cardiologie, Hôpital Pitié-Salpêtrière, 47/83 Bd de l'Hôpital-75013 Paris. jean-philippe.metzger@psl.aphp.fr
authors.forename: Jean-Philippe
authors.initials: JP
authors.lastname: Metzger
mesh_terms: D000077284:Abciximab; D054058:Acute Coronary Syndrome / Q000628:therapy; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects* / Q000401:mortality / Q000639:trends; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003327:Coronary Disease / Q000188:drug therapy / Q000628:therapy; D023903:Coronary Restenosis / Q000517:prevention & control; D006406:Hematoma / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D007022:Hypotension / Q000209:etiology / Q000517:prevention & control; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D015607:Stents
chemical_list: D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D000077284:Abciximab